IPHA vs. DAWN, AKBA, OLMA, TYRA, TERN, TBPH, ARVN, ERAS, SNDL, and MLTX
Should you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Day One Biopharmaceuticals (DAWN), Akebia Therapeutics (AKBA), Olema Pharmaceuticals (OLMA), Tyra Biosciences (TYRA), Terns Pharmaceuticals (TERN), Theravance Biopharma (TBPH), Arvinas (ARVN), Erasca (ERAS), SNDL (SNDL), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.
Innate Pharma vs. Its Competitors
Day One Biopharmaceuticals (NASDAQ:DAWN) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.
Innate Pharma has lower revenue, but higher earnings than Day One Biopharmaceuticals.
Day One Biopharmaceuticals has a beta of -1.26, meaning that its stock price is 226% less volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.
Innate Pharma has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -50.63%. Innate Pharma's return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.
In the previous week, Day One Biopharmaceuticals had 4 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Day One Biopharmaceuticals and 0 mentions for Innate Pharma. Day One Biopharmaceuticals' average media sentiment score of 0.39 beat Innate Pharma's score of 0.00 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media.
88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 6.2% of Day One Biopharmaceuticals shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Day One Biopharmaceuticals currently has a consensus price target of $25.29, suggesting a potential upside of 238.72%. Innate Pharma has a consensus price target of $6.50, suggesting a potential upside of 194.92%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Day One Biopharmaceuticals is more favorable than Innate Pharma.
Summary
Day One Biopharmaceuticals beats Innate Pharma on 8 of the 15 factors compared between the two stocks.
Get Innate Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innate Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:IPHA) was last updated on 10/24/2025 by MarketBeat.com Staff
